开云app官网登录入口网页版-官方正版

#抗体药物#

61篇内容 | 1799人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2205466, encodeId=41ee220546644, content=<a href='/topic/show?id=3750e9165fe' target=_blank style='color:#2F92EE;'>#综述#</a> <a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=收藏！抗体药物的全面综述！, objectType=article, longId=825888, objectId=22c9825888f3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240518/1716047244723_5579292.jpg, objectUrl=/article/show_article.do?id=22c9825888f3, replyNumber=0, likeNumber=117, createdTime=2024-05-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=22c9825888f3, moduleTitle=收藏！抗体药物的全面综述！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=22c9825888f3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2016197, encodeId=61b6201619e24, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=Clin Cancer Res：采用抗CD79B抗体药物偶联物DCDS0780A治疗非霍奇金淋巴瘤, objectType=article, longId=293438, objectId=5c862934382f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c862934382f, replyNumber=0, likeNumber=83, createdTime=2022-10-24, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c862934382f, moduleTitle=Clin Cancer Res：采用抗CD79B抗体药物偶联物DCDS0780A治疗非霍奇金淋巴瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5c862934382f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016199, encodeId=f662201619927, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=2022年2月12日简报：FDA批准首款针对奥密克戎的新抗体药物；意大利取消户外口罩令；英国政府科学家：奥密克戎是个例外，下一个变异毒株或类似德尔塔, objectType=article, longId=295514, objectId=81472955144d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81472955144d, replyNumber=0, likeNumber=76, createdTime=2022-07-15, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81472955144d, moduleTitle=2022年2月12日简报：FDA批准首款针对奥密克戎的新抗体药物；意大利取消户外口罩令；英国政府科学家：奥密克戎是个例外，下一个变异毒株或类似德尔塔, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=81472955144d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016200, encodeId=0bc2201620044, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=JAMA Oncol：抗表皮生长因子受体抗体药物偶联物MRG003治疗晚期实体瘤, objectType=article, longId=727924, objectId=0dbbe2792428, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0dbbe2792428, replyNumber=0, likeNumber=72, createdTime=2022-11-29, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0dbbe2792428, moduleTitle=JAMA Oncol：抗表皮生长因子受体抗体药物偶联物MRG003治疗晚期实体瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0dbbe2792428)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016201, encodeId=91882016201ff, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=百奥赛图与LiberoThera共同开发全人GPCR抗体药物取得里程碑式进展, objectType=article, longId=732978, objectId=3ce1e32978e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ce1e32978e9, replyNumber=0, likeNumber=84, createdTime=2022-10-07, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ce1e32978e9, moduleTitle=百奥赛图与LiberoThera共同开发全人GPCR抗体药物取得里程碑式进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3ce1e32978e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016193, encodeId=6f9e2016193fe, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=LegoChem Biosciences与Iksuda Therapeutics扩大抗体药物偶联物开发许可协议, objectType=article, longId=213183, objectId=364e2131837c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=364e2131837c, replyNumber=0, likeNumber=74, createdTime=2021-07-04, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=364e2131837c, moduleTitle=LegoChem Biosciences与Iksuda Therapeutics扩大抗体药物偶联物开发许可协议, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=364e2131837c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016195, encodeId=1d842016195a5, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=Celltrion的单克隆抗体药物瑞丹维单抗获欧盟委员会批准用于治疗新冠肺炎, objectType=article, longId=220524, objectId=62c1220524a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62c1220524a2, replyNumber=0, likeNumber=89, createdTime=2022-07-02, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62c1220524a2, moduleTitle=Celltrion的单克隆抗体药物瑞丹维单抗获欧盟委员会批准用于治疗新冠肺炎, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=62c1220524a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016198, encodeId=395e2016198c3, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=Iksuda Therapeutics与LegoChem Biosciences签署Her2抗体药物偶联物项目许可协议以深化临床产品线, objectType=article, longId=293894, objectId=b4132938940e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4132938940e, replyNumber=0, likeNumber=81, createdTime=2022-06-07, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4132938940e, moduleTitle=Iksuda Therapeutics与LegoChem Biosciences签署Her2抗体药物偶联物项目许可协议以深化临床产品线, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b4132938940e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016196, encodeId=2990201619682, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, objectType=article, longId=221117, objectId=796122111e42, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=796122111e42, replyNumber=0, likeNumber=0, createdTime=2022-09-11, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=796122111e42, moduleTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=796122111e42)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016194, encodeId=e6442016194ac, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=安进以25亿美元收购Teneobio公司，夯实新型抗体药物领导地位, objectType=article, longId=214968, objectId=29c6214968c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29c6214968c5, replyNumber=0, likeNumber=89, createdTime=2022-06-23, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29c6214968c5, moduleTitle=安进以25亿美元收购Teneobio公司，夯实新型抗体药物领导地位, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=29c6214968c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016183, encodeId=caea2016183b0, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=抗体药物偶联物ILUMYA（tildrakizumab-asmn）治疗中重度斑块状牛皮癣：长期安全性有效性良好, objectType=article, longId=195863, objectId=9d4319586365, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d4319586365, replyNumber=0, likeNumber=95, createdTime=2020-07-12, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d4319586365, moduleTitle=抗体药物偶联物ILUMYA（tildrakizumab-asmn）治疗中重度斑块状牛皮癣：长期安全性有效性良好, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9d4319586365)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016191, encodeId=9a83201619139, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=泰诺麦博与西门子合作打造抗体药物数字化工厂, objectType=article, longId=202880, objectId=58532028804f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58532028804f, replyNumber=0, likeNumber=70, createdTime=2021-05-29, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58532028804f, moduleTitle=泰诺麦博与西门子合作打造抗体药物数字化工厂, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=58532028804f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016181, encodeId=7d9b201618147, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, objectType=article, longId=194432, objectId=19de1944327b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19de1944327b, replyNumber=0, likeNumber=64, createdTime=2020-12-25, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19de1944327b, moduleTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=19de1944327b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016185, encodeId=ad81201618555, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=抗体药物偶联物DS-1062研究范围被扩大，治疗晚期或转移性三阴性乳腺癌, objectType=article, longId=196920, objectId=36881969209a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36881969209a, replyNumber=0, likeNumber=115, createdTime=2020-11-22, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36881969209a, moduleTitle=抗体药物偶联物DS-1062研究范围被扩大，治疗晚期或转移性三阴性乳腺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=36881969209a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016192, encodeId=b9ea2016192a7, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=GSK抗体药物otilimab治疗COVID-19，已在老年患者中显示潜力！, objectType=article, longId=207672, objectId=49f720e67299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49f720e67299, replyNumber=0, likeNumber=81, createdTime=2021-04-29, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49f720e67299, moduleTitle=GSK抗体药物otilimab治疗COVID-19，已在老年患者中显示潜力！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=49f720e67299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016184, encodeId=8fbc2016184f3, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=抗体药物研发中具有重要作用的抗独特型抗体研究介绍, objectType=article, longId=196382, objectId=24941963827c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24941963827c, replyNumber=0, likeNumber=103, createdTime=2021-03-11, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24941963827c, moduleTitle=抗体药物研发中具有重要作用的抗独特型抗体研究介绍, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=24941963827c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016187, encodeId=8d65201618e2e, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=靶向HER2的抗体药物偶联物ENHERTU治疗乳腺癌，获得欧洲药品管理局的快速审查, objectType=article, longId=197261, objectId=e32219e26199, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e32219e26199, replyNumber=0, likeNumber=70, createdTime=2021-05-11, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e32219e26199, moduleTitle=靶向HER2的抗体药物偶联物ENHERTU治疗乳腺癌，获得欧洲药品管理局的快速审查, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e32219e26199)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016190, encodeId=540820161903c, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=抗体药物偶联物[Vic-]曲妥珠单抗 Duocarmazine治疗HER2阳性实体瘤：已启动I期临床研究, objectType=article, longId=199921, objectId=e4ad199921fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4ad199921fd, replyNumber=0, likeNumber=99, createdTime=2020-11-12, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4ad199921fd, moduleTitle=抗体药物偶联物[Vic-]曲妥珠单抗 Duocarmazine治疗HER2阳性实体瘤：已启动I期临床研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e4ad199921fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016186, encodeId=bc98201618608, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=抗体药物偶联物Trodelvy显著改善三阴性乳腺癌患者的PFS：III期研究达到终点, objectType=article, longId=197187, objectId=f91619e187c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f91619e187c8, replyNumber=0, likeNumber=78, createdTime=2020-07-17, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f91619e187c8, moduleTitle=抗体药物偶联物Trodelvy显著改善三阴性乳腺癌患者的PFS：III期研究达到终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f91619e187c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016180, encodeId=307520161808c, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准, objectType=article, longId=194256, objectId=5af31942566d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5af31942566d, replyNumber=0, likeNumber=75, createdTime=2020-12-28, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5af31942566d, moduleTitle=喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5af31942566d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

抗体药物

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#综述# #抗体药物#

收藏！抗体药物的全面综述！

2024-05-18发表于上海

docwu2019 (审核中...)

前往app查看评论内容

#抗体药物#

Clin Cancer Res：采用抗CD79B抗体药物偶联物DCDS0780A治疗非霍奇金淋巴瘤

2022-10-24

docwu2019 (审核中...)

前往app查看评论内容

#抗体药物#

2022年2月12日简报：FDA批准首款针对奥密克戎的新抗体药物；意大利取消户外口罩令；英国政府科学家：奥密克戎是个例外，下一个变异毒株或类似德尔塔

2022-07-15

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

JAMA Oncol：抗表皮生长因子受体抗体药物偶联物MRG003治疗晚期实体瘤

2022-11-29

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

百奥赛图与LiberoThera共同开发全人GPCR抗体药物取得里程碑式进展

2022-10-07

docwu2019 (审核中...)

前往app查看评论内容

#抗体药物#

LegoChem Biosciences与Iksuda Therapeutics扩大抗体药物偶联物开发许可协议

2021-07-04

docwu2019 (审核中...)

前往app查看评论内容

#抗体药物#

Celltrion的单克隆抗体药物瑞丹维单抗获欧盟委员会批准用于治疗新冠肺炎

2022-07-02

docwu2019 (审核中...)

前往app查看评论内容

#抗体药物#

Iksuda Therapeutics与LegoChem Biosciences签署Her2抗体药物偶联物项目许可协议以深化临床产品线

2022-06-07

docwu2019 (审核中...)

前往app查看评论内容

#抗体药物#

靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌

2022-09-11

docwu2019 (审核中...)

前往app查看评论内容

#抗体药物#

安进以25亿美元收购Teneobio公司，夯实新型抗体药物领导地位

2022-06-23

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

抗体药物偶联物ILUMYA（tildrakizumab-asmn）治疗中重度斑块状牛皮癣：长期安全性有效性良好

2020-07-12

docwu2019 (审核中...)

前往app查看评论内容

#抗体药物#

泰诺麦博与西门子合作打造抗体药物数字化工厂

2021-05-29

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌

2020-12-25

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

抗体药物偶联物DS-1062研究范围被扩大，治疗晚期或转移性三阴性乳腺癌

2020-11-22

docwu2019 (审核中...)

前往app查看评论内容

#抗体药物#

GSK抗体药物otilimab治疗COVID-19，已在老年患者中显示潜力！

2021-04-29

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

抗体药物研发中具有重要作用的抗独特型抗体研究介绍

2021-03-11

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

靶向HER2的抗体药物偶联物ENHERTU治疗乳腺癌，获得欧洲药品管理局的快速审查

2021-05-11

docwu2019 (审核中...)

前往app查看评论内容

#抗体药物#

抗体药物偶联物[Vic-]曲妥珠单抗 Duocarmazine治疗HER2阳性实体瘤：已启动I期临床研究

2020-11-12

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

抗体药物偶联物Trodelvy显著改善三阴性乳腺癌患者的PFS：III期研究达到终点

2020-07-17

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准

2020-12-28

科室
- - 订阅+
  - 更多科室
工具
服务